Open AccessFormulation and Characterisation of RGD-FBG Based Nanoscaffolds as Novel Anti-Cancer Drug Delivery System
Author(s) -
Deepa Patel,
Drashti Pathak
Publication year - 2022
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2022/v34i8b35479
Subject(s) - zeta potential , pharmaceutics , drug delivery , conjugate , drug , biomedical engineering , nanotechnology , emulsion , materials science , chromatography , nanoparticle , chemistry , medicine , pharmacology , organic chemistry , mathematics , mathematical analysis
Aims/Objective: To formulate and evaluate RGD sequenced fibrin/fibrinogen based nanoscaffolds (acid-labile linker) for the treatment of brain tumor targeting to achieve an acid-triggered drug release under a mild acidic condition in tumor.
Place and Duration of Study: Department of Pharmaceutics, Parul Institute of Pharmacy and Research, Parul University, Vadodara, between 2017 to 2021.
Methodology: Nanoscaffolds was prepared with Drug–linker–Fbg conjugate solution, using modified water-in-oil (W/O) emulsification/solvent extraction method. The conjugate solution was constantly injected in soya lecithin (100 ml) using a syringe (1 ml/min) and stirred using Magnetic stirrer for 30 minutes to form stable a W/O emulsion. The present investigation was aimed to evaluate with Particle size, Zeta potential measurement, Percent drug entrapment, Transmission electron microscopy.
Results: As per Evaluation parameters were performed such as Particle size measured as 151.8±2.02 nm to 157.4 ± 3.81 nm. Zeta Potential was found that -37.1±6.32, Percent Drug Entrapment was 91.4±0.37 which indicates that the drug release of lyophilised FBG based nanoscaffolds was indicatively higher as compared to FBG based nanoscaffolds (alone).
Conclusion: As per the study design the formulated nanoscaffolds were found to impart the drug release based on their particle size and percent drug entrapment and hence fights against cancer cells in brain by their EDC-NHS chemistry. Drug of choice Everolimus along with Fbg based nanoscaffolds offers better biocompatibility by exposing dual responsiveness at acidic environment in tumors. The results of in-vitro drug release reveals the better uptake of drug at targeted site of action.